Northern Trust Corp Has $128.46 Million Holdings in Insmed, Inc. $INSM

Key Points

• Northern Trust Corp reduced its holdings in Insmed, Inc. by 3.8% in the first quarter, owning approximately 1.68 million shares valued at $128.46 million.
• Insmed's CFO and COO recently sold over 83,000 shares of the company's stock, reflecting a significant decrease in their ownership positions.
• Several analysts have upgraded their price targets for Insmed, with Mizuho raising it from $130 to $165, and over 16 analysts currently rate the stock as a Buy.

Northern Trust Corp lessened its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 3.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,683,838 shares of the biopharmaceutical company's stock after selling 66,804 shares during the period. Northern Trust Corp owned about 0.93% of Insmed worth $128,460,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP acquired a new stake in shares of Insmed during the 4th quarter worth approximately $28,000. NBC Securities Inc. acquired a new stake in shares of Insmed during the 1st quarter worth approximately $49,000. Versant Capital Management Inc boosted its position in shares of Insmed by 546.3% during the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 590 shares in the last quarter. Finally, Signaturefd LLC boosted its position in shares of Insmed by 60.0% during the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 325 shares in the last quarter.

Insider Activity

In other news, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the transaction, the chief financial officer owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Roger Adsett sold 25,000 shares of the firm's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the transaction, the chief operating officer directly owned 105,637 shares of the company's stock, valued at $13,477,168.46. The trade was a 19.14% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 539,694 shares of company stock valued at $53,144,604. 3.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

INSM has been the topic of several analyst reports. Mizuho increased their price target on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Jefferies Financial Group increased their price target on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. HC Wainwright increased their price target on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. William Blair began coverage on shares of Insmed in a research report on Wednesday. They set an "outperform" rating on the stock. Finally, Bank of America increased their price objective on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $132.57.

Insmed Price Performance

INSM stock opened at $131.88 on Friday. The company has a fifty day moving average price of $107.48 and a 200-day moving average price of $85.66. The company has a market capitalization of $27.88 billion, a P/E ratio of -23.10 and a beta of 0.95. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $133.56. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. Insmed's revenue was up 18.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.